Shionogi & Co., Ltd. (TYO:4507)
Japan
· Delayed Price · Currency is JPY | Market Cap | 2.93T |
| Revenue (ttm) | 465.38B |
| Net Income (ttm) | 194.82B |
| Shares Out | 850.98M |
| EPS (ttm) | 228.94 |
| PE Ratio | 15.03 |
| Forward PE | 13.81 |
| Dividend | 66.00 (1.93%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 2,574,700 |
| Average Volume | 2,759,460 |
| Open | 3,493.00 |
| Previous Close | 3,418.00 |
| Day's Range | 3,425.00 - 3,515.00 |
| 52-Week Range | 2,153.50 - 3,705.00 |
| Beta | 0.02 |
| RSI | 52.01 |
| Earnings Date | May 8, 2026 |
About Shionogi &
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Osaka, Japan. [Read more]
Financial Performance
In fiscal year 2025, Shionogi &'s revenue was 438.27 billion, an increase of 0.73% compared to the previous year's 435.08 billion. Earnings were 170.44 billion, an increase of 5.19%.
Financial StatementsNews
Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits
Japan's Shionogi & Co said on Tuesday it would pay $2.13 billion for new shares in joint venture ViiV Healthcare, increasing its stake in the HIV drugmaker to 21.7% as U.S. drugmaker Pfizer exits its ...
Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2025 Earnings Conference Call July 28, 2025 3:30 AM ET Company Participants John A.
Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q3 2024 Earnings Conference Call January 31, 2025 3:30 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications Masako Kudou - VP, Finance & Accou...
Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q2 2024 Earnings Call Transcript October 29, 2024 2:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Isao Teshirogi - Chair...
Shionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2024 Earnings Conference Call July 29, 2024 4:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Masako Kudou - Vice Presi...
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
OSAKA, Japan & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and Maze Therapeutic...
Shionogi & Co., Ltd. (SGIOF) Q2 2023 Earnings Conference Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOF) Q2 2023 Earnings Conference Call October 31, 2023 9:30 PM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications Isao Teshirogi - Representative Di...
Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOF) Q1 2023 Earnings Conference Call July 31, 2023 5:15 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications John Keller - Senior Executive Office...
Shionogi: Likely The Last Viable COVID Play
Xocova is an approved-in-Japan COVID antiviral. Other COVID investments are causing valuations to fall as their opportunities subside.
Shionogi & Co., Ltd. (SGIOF) Q3 2022 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOF) Q3 2022 Earnings Conference Call January 30, 2023 1:00 AM ET Company Participants Yoshimasa Kyokawa - Investor Relations Masako Kudou - Vice President, Finance and A...